Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Ferguson CindyOwnership Type:Direct OwnershipSecurities:restricted stock unitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-163Price:--
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Ferguson CindyOwnership Type:Direct OwnershipSecurities:common stockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-45Price:$440.80
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Ferguson CindyOwnership Type:Direct OwnershipSecurities:common stockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:163Price:--
-
Jan 02, 2024 (filed on Jan 03, 2024)Insider Name:Ferguson CindyOwnership Type:Direct OwnershipSecurities:restricted stock unitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14Price:--
-
Jan 02, 2024 (filed on Jan 03, 2024)Insider Name:Stupp John P JrOwnership Type:Direct OwnershipSecurities:stock unitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10Price:--
-
Dec 01, 2023 (filed on Dec 01, 2023)Insider Name:Athey Preston GOwnership Type:Direct OwnershipSecurities:common stockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:300Price:$319.68
-
Nov 24, 2023 (filed on Nov 27, 2023)Insider Name:Ferguson CindyOwnership Type:Direct OwnershipSecurities:restricted stock unitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:480Price:--
-
Nov 16, 2023 (filed on Nov 16, 2023)Insider Name:Battat David AOwnership Type:Direct OwnershipSecurities:common stockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:300Price:$300.00
-
Sep 20, 2023 (filed on Sep 21, 2023)Insider Name:Bankes JeannetteOwnership Type:Direct OwnershipSecurities:common stockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:186Price:$444.03
-
Aug 15, 2023 (filed on Aug 18, 2023)Insider Name:Athey Preston GOwnership Type:Direct OwnershipSecurities:common stockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:200Price:$523.35
Filings by filing date
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Ferguson CindyOwnership Type:Direct OwnershipSecurities:restricted stock unitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-163Price:--
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Ferguson CindyOwnership Type:Direct OwnershipSecurities:common stockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-45Price:$440.80
-
Mar 08, 2024 (filed on Mar 11, 2024)Insider Name:Ferguson CindyOwnership Type:Direct OwnershipSecurities:common stockNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:163Price:--
-
Jan 02, 2024 (filed on Jan 03, 2024)Insider Name:Ferguson CindyOwnership Type:Direct OwnershipSecurities:restricted stock unitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:14Price:--
-
Jan 02, 2024 (filed on Jan 03, 2024)Insider Name:Stupp John P JrOwnership Type:Direct OwnershipSecurities:stock unitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:10Price:--
-
Dec 01, 2023 (filed on Dec 01, 2023)Insider Name:Athey Preston GOwnership Type:Direct OwnershipSecurities:common stockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:300Price:$319.68
-
Nov 24, 2023 (filed on Nov 27, 2023)Insider Name:Ferguson CindyOwnership Type:Direct OwnershipSecurities:restricted stock unitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:480Price:--
-
Nov 16, 2023 (filed on Nov 16, 2023)Insider Name:Battat David AOwnership Type:Direct OwnershipSecurities:common stockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:300Price:$300.00
-
Sep 20, 2023 (filed on Sep 21, 2023)Insider Name:Bankes JeannetteOwnership Type:Direct OwnershipSecurities:common stockNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:186Price:$444.03
-
Aug 15, 2023 (filed on Aug 18, 2023)Insider Name:Athey Preston GOwnership Type:Direct OwnershipSecurities:common stockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:200Price:$523.35
News
Biz Brief
Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | One Allentown Parkway ALLEN TX 75002 |
Tel: | N/A |
Website: | https://atrioncorp.com |
IR: | See website |
Key People | ||
Emile A. Battat Chairman of the Board, Chairman of the Board of Halkey-Roberts Corporation | David A. Battat President, Chief Executive Officer; President of Halkey-Roberts | Cindy Ferguson Vice President, Chief Financial Officer, Treasurer, Secretary |
Business Overview |
Atrion Corporation develops and manufactures products, primarily for medical applications. The Company's medical products are used in a number of fields including fluid delivery, cardiovascular, and ophthalmic applications. It has developed a variety of proprietary valves designed to precisely fill, hold, and release and/or remove controlled amounts of fluids, including blood and drugs, or gasses on demand for use in areas such as intubation, intravenous, catheter, and other applications in fields including anesthesia and oncology. The core of its cardiovascular products is its Myocardial Protection System, a technology that is the only open-heart surgery system that delivers to the heart essential fluids and medications, mixes critical drugs, and controls temperature, pressure, and other important variables. The Company also manufactures a line of balloon catheters used in the treatment of nasolacrimal duct obstruction in children and adults. |
Financial Overview |
For the fiscal year ended 31 December 2023, Atrion Corp revenues decreased 8% to $169.3M. Net income decreased 45% to $19.4M. Revenues reflect Fluid Delivery segment decrease of 15% to $71.1M, Other segment decrease of 24% to $19.8M, All other Regions segment decrease of 13% to $37.8M, European Union segment decrease of 17% to $25.1M. Net income also reflects Selling/General/Admin. Expense increase of 13% to $21.7M (expense). |
Employees: | 712 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $809.52M as of Dec 31, 2023 |
Annual revenue (TTM): | $169.33M as of Dec 31, 2023 |
EBITDA (TTM): | $37.68M as of Dec 31, 2023 |
Net annual income (TTM): | $19.41M as of Dec 31, 2023 |
Free cash flow (TTM): | -$17.62M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 1,759,836 as of Feb 8, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |